Introduction and Objectives Asthma accounts for an economic loss of C ¼ 72 billion annually in the 28 countries of the European Union with a monetised value of DALYs cost of C ¼ 38 billion. One of the key priorities in asthma management is achieving asthma control. It is crucial to understand whether providing a minimally clinical important difference (MID) of the asthma control test (ACT) score can bring better clinical, utility and economic outcomes. Aim To test whether the A.B.O.V.E. ASTHMA (Achieving-Better-Outcomes-and-Value-for-Everybody-in-Asthma) tool works in terms of securing the MID in ACT and, in doing so, we can provide positive outcomes for patients, payers, providers and policy makers. Methods Using the data obtained from the Italian Medicines Use Review (I-MUR) cluster randomised controlled trial (C-RCT; 2014 -2015 involving 1263 asthma patients and 283 pharmacists in Italy, we tested whether A.B.O.V.E. ASTHMA was able to (1) link a clinical outcome (ACT score) to economic and utility dimensions; (2) secure a MID improvement in ACT and the outcomes attached in terms of cost savings Abstract P200 Table 1 The calculation of the cost-saving for the NHS was estimated for a population of 1,000 asthma patients.
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for the healthcare provider and gains in health utility (% of being in perfect health).
Results Data from the C-RCT showed that after receiving the A.B.O.V.E. ASTHMA intervention, patients improved their asthma control, assessed by the ACT, shifting from not controlled (RED) towards partially controlled (YELLOW), and fully controlled (GREEN) groups. Asthma control improved in the vast majority of patients (median ACT score was 19 at baseline, 20 at 3 month and 21 at 6 month post intervention). The number of patients who were on MID target and reached the GREEN group at 3 and 6 months were 129 (15.8%) and 162 (19.9%) respectively. The overall annual cost savings per 1000 patients attached to the shift towards the MID target was equal to: 3 46 012 euros (NHS) at 3 months and increased to 4 25 483 euros (NHS) at 6 months (see Table) . Health utility gains were equal to 0.9 and 0.29 years in full health, respectively. Conclusions The A.B.O.V.E. ASTHMA tool can secure MID in ATC and, in doing so, better outcomes in terms of clinical, utility and economic results. The calculation of the cost-saving for the NHS was estimated for a population of 1000 asthma patients
P201 PARKRUN DYSPNOEA -ISN'T IT ALL EXERCISE-INDUCED ASTHMA?
Introduction A broad differential diagnosis exists for exerciseinduced dyspnoea (EID) and wheeze in young athletic individuals, however these symptoms are often treated as presumed exercise-induced asthma (EIA). A key differential diagnosis for EIA is exercise-induced laryngeal obstruction (EILO); a condition characterised by transient closure of the larynx precipitating stridor during exercise. Recent studies reveal a prevalence of 5%-7% in Scandinavian adolescents, however the prevalence of EILO in the UK is currently unclear. Objectives To assess the prevalence of stridor and EID in a cohort of recreationally active individuals. Methods Cross-sectional field-based evaluation of the prevalence of stridor and EID in a cohort of individuals completing a 5 km Parkrun event in Northern England. Eighty-five adults (male: n=43) (mean ±SD) age: 39±15 years) were enrolled. Pre-race, respiratory symptoms in combination with an Allergy Questionnaire for Athletes [AQUA score:5) and baseline spirometry were assessed. Immediately post-race, breathing was monitored continuously using an audio recording device for 15 min or until full recovery (i.e., resting tidal breathing had resumed). Recordings were analysed retrospectively and coded for signs of the predominant respiratory noise: 0=nil; 1=inspiratory stridor; 2=expiratory wheeze; 3=combined stridor+wheeze; 4=cough. Results The majority of the cohort (93%) had normal resting lung function. Despite this, the prevalence of troublesome respiratory symptoms was 46% (D12 score: 6±5 and AQUA score: 13±6). Almost one third of the cohort (28%) had at least one respiratory sign: inspiratory stridor (n=9; 11%), expiratory wheeze (n=7; 8%), combined stridor +wheeze (n=6; 7%); cough (n=2; 2%). Of these, over one fifth (21%) had both a symptom and sign of respiratory dysfunction with sign of stridor and EID the most common (14%) (figure 1). Conclusion The prevalence of stridor and EID was 14% in recreationally active individuals completing a Parkrun event. Further work is needed to determine if this relates to objective evidence of EILO however these findings indicate a prevalence in keeping with published series.
